Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?"
Antimicrob Agents Chemother
.
2021 May 18;65(6):e00465-21.
doi: 10.1128/AAC.00465-21.
Print 2021 May 18.
Authors
A-G Märtson
#
1
,
J M Boonstra
#
1
,
I Sandaradura
2
3
,
J G W Kosterink
1
4
,
T S van der Werf
5
6
,
D J E Marriott
7
8
,
J G Zijlstra
9
,
D J Touw
1
,
J W C Alffenaar
10
3
11
Affiliations
1
University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands.
2
The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia.
3
Westmead Hospital, Sydney, Australia.
4
University of Groningen, Department of Pharmacy, Section of Pharmacotherapy and Pharmaceutical Care, Groningen, the Netherlands.
5
University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, the Netherlands.
6
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands.
7
St. Vincent's Clinical School, University of New South Wales, Kensington, NSW, Australia.
8
Department of Clinical Microbiology and Infectious Diseases, St. Vincent's Hospital, Darlinghurst, NSW, Australia.
9
University of Groningen, University Medical Center Groningen, Department of Critical Care, Groningen, the Netherlands.
10
The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia johannes.alffenaar@sydney.edu.au.
11
Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.
#
Contributed equally.
PMID:
33782002
PMCID:
PMC8316007
DOI:
10.1128/AAC.00465-21
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Candidiasis, Invasive*
Critical Illness
Fluconazole*
Humans
Substances
Fluconazole